Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

29.71
+0.43001.47%
Post-market: 29.710.00000.00%19:30 EDT
Volume:1.53M
Turnover:44.93M
Market Cap:3.78B
PE:-7.69
High:29.87
Open:29.18
Low:28.68
Close:29.28
52wk High:31.74
52wk Low:10.55
Shares:127.33M
Float Shares:89.84M
Volume Ratio:1.76
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:8.15
PE(LYR):-9.03

Loading ...

Arcus Biosciences to Present at Citi 2026 Biotech Back to School Conference

Reuters
·
Aug 27

Arcus Biosciences Chief Accounting Officer Alexander Azoy Sells 2,827 Shares for $84,810

Reuters
·
Aug 25

What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders

Simply Wall St.
·
Aug 16

Arcus Biosciences Memberi Hibah Induksi: Opsi 2.850 Saham Dan 1.450 RSU Untuk Karyawan Baru

Reuters
·
Aug 12

Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating

MT Newswires Live
·
Aug 10

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends

Reuters
·
Aug 07

Arcus Biosciences Price Target Raised to $43.00/Share from $41.00 by Wedbush

Dow Jones
·
Aug 06

Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

Agenus Q2 Revenue Rises on Access and Royalty Income

Reuters
·
Aug 06

Arcus Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Arcus Biosciences Q2 FY26 Net Loss Widens to USD 91 Million; Revenue Drops 74.38% to USD 41 Million

Reuters
·
Aug 06

Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate

Benzinga Earnings
·
Aug 06

Arcus Biosciences Q2 Pretax Profit USD -91 Million

Reuters
·
Aug 06

Arcus Biosciences Inc Expected to Post a Loss of 90 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?

Simply Wall St.
·
Aug 03

Bank of America Securities Sticks to Their Hold Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Aug 03

BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25

MT Newswires Live
·
Aug 03